Ranbaxy Sees Better Days Ahead With The Launch Of Valtrex Generic In U.S.
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - There is finally some positive news for India's Ranbaxy as it launched the generic versions of GlaxoSmithKline's herpes treatment Valtrex (valacyclovir) Nov. 25 in the U.S
You may also be interested in...
Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To Ohm Labs While Valacyclovir Rakes Big Gains
MUMBAI - Ranbaxy - the Indian affiliate of Daiichi Sankyo - is believed to have transferred its abbreviated new drug application filing for Lipitor to its New Jersey-based Ohm Labs facility, after U.S. FDA imposed import restrictions last summer on two of its biggest manufactuirng facilities in India
Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To Ohm Labs While Valacyclovir Rakes Big Gains
MUMBAI - Ranbaxy - the Indian affiliate of Daiichi Sankyo - is believed to have transferred its abbreviated new drug application filing for Lipitor to its New Jersey-based Ohm Labs facility, after U.S. FDA imposed import restrictions last summer on two of its biggest manufactuirng facilities in India
Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To U.S. Ohm Labs After FDA Crackdown
Billings for valacyclovir, generic Valtrex, which Ranbaxy shifted earlier to its New Jersey affiliate, reached $100 million within the first week of the U.S. launch.